Trastuzumab, marketed originally as Herceptin by Roche, is a recombinant humanized monoclonal antibody that targets the extracellular domain of HER2, a transmembrane tyrosine kinase receptor amplified or overexpressed in 15 to 30 percent of breast cancers. That molecular abnormality historically signaled aggressive disease and poor prognosis, but trastuzumab changed the trajectory of the illness. Approved by the US Food and Drug Administration in 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, the antibody, when combined with chemotherapy, improves overall survival by roughly one third in patients with early disease. Breast cancer itself remains the most commonly diagnosed cancer in women worldwide, with more than 2.3 million new cases and 666,000 deaths recorded in 2022, which makes reliable, affordable access to this therapy a global health priority.

The problem is cost. Biologic medicines such as trastuzumab are produced in living cells and are far more expensive to manufacture than small-molecule pills, a barrier that limits access for many patients, particularly in developing countries. After the patent on reference trastuzumab expired, several biosimilars were developed and approved by the FDA and the EMA. Unlike generic versions of chemical drugs, which can be shown to be identical through simple chemical analysis, biosimilars must demonstrate that they are highly similar in structure and function and that any differences carry no clinically meaningful consequences. That is where equivalence trials such as this one, known as study EGC002, come in.

The trial recruited women aged 18 to 65 with primary, operable, histologically confirmed HER2-positive early breast cancer, defined by a tumor larger than two centimeters with no metastases beyond the axillary lymph nodes. All participants first received four cycles of anthracycline-based chemotherapy with epirubicin and cyclophosphamide. They were then randomized one to one to receive either EG12014 or reference trastuzumab alongside paclitaxel, with the antibody given as an 8 mg/kg loading dose followed by 6 mg/kg maintenance infusions every three weeks. After surgery, patients continued adjuvant therapy to complete twelve months of trastuzumab treatment. Crucially, patients who had received the reference drug were rerandomized after surgery to either stay on it or switch to the biosimilar, creating a dedicated switch arm of 188 patients.

The primary endpoint was pathological complete response, or pCR, assessed by a central laboratory blinded to treatment assignment. This measure, defined as the absence of residual invasive cancer in the resected breast specimen and all sampled lymph nodes regardless of residual ductal carcinoma in situ, is endorsed by the FDA as a valid endpoint for neoadjuvant trials in high-risk early breast cancer. The results were strikingly close: 47.2 percent of patients on EG12014 achieved pCR compared with 47.8 percent on reference trastuzumab. The risk difference was minus 0.004, with a 95 percent confidence interval of minus 0.072 to 0.065, falling entirely within the EMA’s predefined equivalence margin of minus 0.13 to 0.13. The risk ratio analysis, required by the FDA, produced a relative risk of 0.992 with a 90 percent confidence interval of 0.880 to 1.118, comfortably inside the margin of 0.741 to 1.349.

Secondary endpoints reinforced the picture of equivalence. Rates of pCR under alternative definitions, objective response before surgery, event-free survival, and overall survival were all comparable between the arms. Subgroup analyses by age, race, hormone receptor status, performance status, geographic region, and tumor stage were generally supportive, though the authors caution that some categories were too small for firm conclusions. The trial was powered at 95 percent for the primary risk-difference analysis, assuming a true pCR rate of 35 percent in each arm, giving the result substantial statistical credibility.

Safety data were equally reassuring. Treatment-emergent adverse events were overwhelmingly mild to moderate, and the most frequent events, including alopecia in roughly 85 to 88 percent of patients, nausea, asthenia, and neutropenia, reflect the known toxicity of the chemotherapy backbone rather than the antibody itself. Serious adverse events occurred at similar rates across arms, between 14.4 and 18.6 percent of patients, and were dominated by COVID-19 infections during the pandemic period. Nine deaths were recorded, four in the EG12014 arm and five in the reference arm, all judged unrelated to trastuzumab and mostly linked to metastasis of the underlying cancer. Only 2.5 percent of patients discontinued treatment because of adverse events, with decreased ejection fraction, a recognized cardiac risk of HER2 blockade, the most common reason.

Immunogenicity and pharmacokinetics completed the biosimilarity picture. De novo antidrug antibodies appeared in only 3.3 percent of the EG12014 group, 2.7 percent of the switch group, and 4.8 percent of the reference group, and no patient developed neutralizing antibodies. Serum drug concentrations were comparable at every measured time point, and a population pharmacokinetic analysis using identical two-compartment models for both products confirmed that baseline body weight was the sole significant predictor of drug exposure in both arms. Importantly, the 188 patients who switched from reference trastuzumab to EG12014 after surgery showed no change in safety, immunogenicity, or drug levels, a finding that carries practical weight for health systems that may substitute biosimilars mid-treatment. Only one other trastuzumab biosimilar program, ABP 980, has incorporated a similar switch design into its pivotal trial.

The study weathered an extraordinary real-world stress test: the COVID-19 pandemic struck while enrollment was still underway, with the last patient randomized on March 24, 2020. Eighty-four infections were reported among participants, and some patients experienced delays in surgery or treatment, but these disruptions affected both arms similarly and did not alter the equivalence conclusion. The authors also acknowledge limitations, including a predominantly White, European cohort and the exclusion of male patients, whose breast cancer is rare. They note that current standards of care increasingly pair trastuzumab with a second HER2-targeting drug, pertuzumab, and suggest EG12014 could serve as the trastuzumab component in such combinations. With analytical comparability, Phase I bioequivalence data, and now Phase III clinical equivalence all aligned, EG12014 stands as a fully validated alternative, one that regulators hope will stimulate price competition, ease pressure on health systems, and extend life-saving targeted therapy to more of the millions of women diagnosed with breast cancer each year.

Subject of Research: Clinical equivalence of the trastuzumab biosimilar EG12014 with reference trastuzumab in HER2-positive early breast cancer

Article Title: Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study

Article References: Huang, C.-S., Dzagnidze, G., Grohmann-Izay, B., Liu, L.-C., Llinás-Quintero, N., Lin, A.-N., Mishra, A. K., Pominchuk, D., Prokharau, A., Rapoport, B. L., Semiglazov, V., Tseng, L.-M., Ruiz, E. Y., & Loibl, S. (2026). Efficacy and Safety of EG12014 (Biosimilar Trastuzumab) Compared to Reference Trastuzumab in HER2-Positive Early Breast Cancer: A Phase III Randomized Study. Advances in Therapy. https://doi.org/10.1007/s12325-026-03781-3

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03781-3

Keywords: trastuzumab, biosimilar, EG12014, HER2-positive breast cancer, Phase III trial, pathological complete response, neoadjuvant therapy, adjuvant therapy, immunogenicity, pharmacokinetics, EMA approval, early breast cancer

The research, conducted at Hospital Canselor Tuanku Muhriz of Universiti Kebangsaan Malaysia and published in BMC Cancer, examined 241 women with clinically node-negative early breast cancer, all staged cT1–2N0M0, who underwent sentinel lymph node biopsy between January 2018 and December 2025. The team, led by surgeon Hadija Mustamin together with pathologists and community health researchers, asked a deceptively simple question: does the density of tumour-infiltrating lymphocytes, or TILs, in the tumour stroma correlate with whether cancer cells are found in the sentinel node?

The findings were striking. Among the cohort, 67 patients — 27.8 percent — had metastasis to the sentinel lymph node. But the distribution of that risk was far from even. When pathologists graded stromal TIL levels according to the internationally accepted 2014 guidelines of the International TILs Working Group, they found that two-thirds of the patients fell into the low-TIL category, 17.4 percent into the intermediate category, and 16.6 percent into the high category. Critically, the highest proportion of nodal metastasis occurred in the group with the fewest infiltrating lymphocytes, a statistically significant association with a p value of 0.023.

To understand why this matters, one must appreciate what TILs actually represent. Tumour-infiltrating lymphocytes are immune cells — predominantly T cells — that have migrated from the bloodstream into the tumour microenvironment, a biological indication that the host immune system has recognised the malignancy and mounted a response. In recent years, TIL assessment has graduated from a curiosity of tumour immunology to a practical, reproducible pathology metric. In triple-negative and HER2-positive breast cancers, high TIL counts are already associated with better responses to neoadjuvant chemotherapy and improved survival. What this new study adds is a potential role in the preoperative and perioperative decision-making around the axilla.

The statistical backbone of the study was a two-stage logistic regression strategy. The researchers first screened clinicopathological variables — tumour size, histological type, grade, lymphovascular invasion, hormone receptor status and TIL category — using univariable analyses, and then entered any variable with a p value below 0.25 into a multivariable model. After adjustment, two factors emerged as independent predictors of sentinel node involvement. Higher TIL levels were associated with lower odds of metastasis, with an adjusted odds ratio of 0.977 per unit increase (95 percent confidence interval 0.961–0.994; p = 0.007). Lymphovascular invasion, the histological evidence of tumour cells invading blood or lymphatic vessels, was independently associated with nodal spread, carrying an adjusted odds ratio of 0.290 (95 percent CI 0.156–0.537; p < 0.001), meaning its presence substantially raised the odds of metastasis.

Interestingly, tumour size — long regarded as a cornerstone of nodal risk prediction — was associated with sentinel lymph node metastasis in the univariable analysis but lost its significance once other factors were accounted for. That statistical humility is itself informative: it suggests that within this cohort of small, clinically node-negative tumours, the biology of the tumour microenvironment and the presence of lymphovascular invasion may carry more predictive weight than size alone. If validated, such a shift could change how pathologists’ reports are weighted in surgical planning.

The clinical implications are potentially significant. Sentinel lymph node biopsy, while far less morbid than full axillary dissection, still carries risks of lymphoedema, seroma, nerve injury and infection. A reliable, cheap, microscope-based biomarker that stratifies nodal risk before surgery could, in principle, help identify patients in whom biopsy yields the greatest information, or in the longer term, support more selective approaches to axillary staging. Because TIL scoring requires only routine haematoxylin and eosin slides and a trained pathologist, it is vastly more accessible than genomic assays or advanced imaging, an especially important consideration in resource-constrained health systems such as much of Southeast Asia.

The authors are careful, and appropriately so, about the limits of their work. This was a single-centre, cross-sectional study, which captures association but cannot establish that low TIL levels cause nodal spread. Only a single pathologist scored the slides, raising questions about inter-observer reproducibility that multi-reader studies would need to resolve. The cohort spans tumours of all molecular subtypes, and TIL biology differs markedly between triple-negative, HER2-positive and luminal cancers; subtype-specific analyses in larger, prospective cohorts with external validation will be required before TIL assessment can be folded into clinically useful prediction models for nodal status. The study received no external funding, and the analysis reflects institutional records from one Malaysian tertiary centre.

Nevertheless, the study joins a rapidly expanding body of evidence that the immune microenvironment is not merely a bystander in cancer progression but an active determinant of how tumours behave. A tumour bristling with lymphocytes appears, in this data, to be a tumour less likely to have seeded the regional nodes — a biological narrative that makes intuitive sense, since a robust local immune response may constrain the earliest steps of dissemination. Conversely, an immunologically cold tumour, walled off from immune attack, may enjoy freer rein to invade lymphatic channels and establish footholds downstream.

For patients, the message is not one of immediate change in care — no guideline today spares anyone a sentinel node biopsy on the basis of TIL counts. But it is another step toward a future in which the pathology report of a breast cancer describes not just what the tumour is, but what the body is doing about it. As immunotherapy reshapes oncology and immune biomarkers move from research benches to clinical reports, studies like this one map the terrain where tumour immunology and surgical decision-making converge. Whether the quiet presence of lymphocytes in a tumour’s stroma can one day spare a woman an unnecessary procedure remains to be proven, but this Malaysian cohort offers a compelling early signal that the immune system has been keeping records all along — records pathologists are only now learning to read.

Subject of Research: Association between stromal tumour-infiltrating lymphocyte levels and sentinel lymph node metastasis in early breast cancer

Article Title: Tumour-infiltrating lymphocytes are associated with sentinel lymph node metastasis in early breast cancer: a cross-sectional study

Article References: Tumour-infiltrating lymphocytes are associated with sentinel lymph node metastasis in early breast cancer: a cross-sectional study. (n.d.). https://doi.org/10.1186/s12885-026-17012-z

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17012-z

Keywords: breast cancer, tumour-infiltrating lymphocytes, sentinel lymph node metastasis, tumour immune microenvironment, lymphovascular invasion, sentinel lymph node biopsy, cancer metastasis, tumour immunology, early breast cancer, pathology biomarker, logistic regression, BMC Cancer